Stockpolly
Search
PLSE · NASDAQ · Medical - Instruments & Supplies

Pulse Biosciences (PLSE)

Develops nPulse systems for soft-tissue and atrial-fibrillation ablation.

$52.70
At close+0.61 (+1.17%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000100
Gross profit000000000000
111310121420182020181925
Research & development7877811101211111317
4544610889778
Selling & marketing000000000000
General & administrative4544610880078
Other expenses000000000000
Operating income−11−13−11−12−14−20−18−20−20−18−19−25
110011111111
Interest income110011111111
Other non-operating income0−100−1−1−1−1−1−10−1
Income before tax−11−12−10−11−13−19−17−19−19−17−19−25
Net income from continuing operations−11−12−10−11−13−19−17−19−19−17−19−25
Net income−11−12−10−11−13−19−17−19−19−17−19−25
EPS, basic−$0.19−$0.22−$0.18−$0.20−$0.21−$0.33−$0.25−$0.28−$0.29−$0.26−$0.26−$0.36
EPS, diluted−$0.19−$0.22−$0.18−$0.20−$0.21−$0.33−$0.25−$0.28−$0.29−$0.26−$0.26−$0.36
Weighted average shares, basic555555576158676767676869
Weighted average shares, diluted555555576158676767676869
EBITDA−11−12−10−11−12−19−17−19−19−17−19−25
Depreciation & amortization000000000000
EBIT−11−12−10−11−13−19−17−19−19−17−19−25